会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • INHIBITORS OF CATHEPSIN B
    • CATHEPSIN B的抑制剂
    • WO2009100225A1
    • 2009-08-13
    • PCT/US2009/033229
    • 2009-02-05
    • VIROBAY, INC.HOLSINGER, Leslie
    • HOLSINGER, Leslie
    • A61K38/00
    • A61K38/05
    • The present invention is directed to a method of using compounds of Formula (I) to inhibit Cathepsin B. Specifically the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's Disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory airway disease, and bone and joint disorders, including osteoporosis, osteoarthritis, rheumatoid arthritis, psoriasis, and other autoimmune disorders, liver fibrosis, including liver fibrosis associated with HCV, all types of steatosis (including non-alcoholic steatohepatitis) and alcohol-associated steatohepatitis, non-alcoholic fatty liver disease, forms of pulmonary fibrosis including idiopathic pulmonary fibrosis, pathological diagnosis of interstitial pneumonia following lung biopsy, renal fibrosis, cardiac fibrosis, retinal angiogenesis and fibrosis/gliosis in the eye, schleroderma, and systemic sclerosis. The compopunds of Formula (I) are also useful for treating subjects with both HCV and fibrosis in a mammal, particularly liver fibrosis, and subjects affirmatively diagnosed or at risk for bopth HCV and liver fibrosis.
    • 本发明涉及使用式(I)化合物抑制组织蛋白酶B的方法。具体地,本发明的化合物可用作治疗肿瘤侵袭,转移,阿尔茨海默病,关节炎,炎性疾病等的治疗剂 作为慢性和急性胰腺炎,炎性气道疾病以及骨关节疾病,包括骨质疏松症,骨关节炎,类风湿性关节炎,牛皮癣和其他自身免疫性疾病,肝纤维化,包括与HCV相关的肝纤维化,所有类型的脂肪变性(包括非酒精性 脂肪性肝炎)和酒精性脂肪性肝炎,非酒精性脂肪性肝病,包括特发性肺纤维化的肺纤维化形式,肺活检后间质性肺炎的病理诊断,肾纤维化,心脏纤维化,视网膜血管生成和眼睛纤维化/神经胶质增生,硬皮病 和系统性硬化症。 式(I)的化合物还可用于治疗哺乳动物,特别是肝纤维化中HCV和纤维化两者的受试者,以及肯定诊断或具有肝炎和肝纤维化风险的受试者。
    • 2. 发明公开
    • INHIBITORS OF CATHEPSIN B
    • 组织蛋白酶B-缝边
    • EP2237793A1
    • 2010-10-13
    • EP09709414.8
    • 2009-02-05
    • Virobay, Inc.
    • HOLSINGER, Leslie
    • A61K38/00
    • A61K38/05
    • The present invention is directed to a method of using compounds of Formula (I) to inhibit Cathepsin B. Specifically the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's Disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory airway disease, and bone and joint disorders, including osteoporosis, osteoarthritis, rheumatoid arthritis, psoriasis, and other autoimmune disorders, liver fibrosis, including liver fibrosis associated with HCV, all types of steatosis (including non-alcoholic steatohepatitis) and alcohol-associated steatohepatitis, non-alcoholic fatty liver disease, forms of pulmonary fibrosis including idiopathic pulmonary fibrosis, pathological diagnosis of interstitial pneumonia following lung biopsy, renal fibrosis, cardiac fibrosis, retinal angiogenesis and fibrosis/gliosis in the eye, schleroderma, and systemic sclerosis. The compopunds of Formula (I) are also useful for treating subjects with both HCV and fibrosis in a mammal, particularly liver fibrosis, and subjects affirmatively diagnosed or at risk for bopth HCV and liver fibrosis.